Evaluating the Prognostic Value of MRD Detection in Ovarian Cancer Patients with Low CA125 Levels
A Study for Assessing the Value of Minimal Residual Disease Detection in Disease Monitoring of CA125 Non-sensitive Ovarian Cancer Patients
This study is testing if checking for tiny amounts of cancer DNA in the blood can help predict the risk of ovarian cancer coming back in patients with low CA125 levels.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 35 (estimated) |
| Sex | Female |
| Sponsor | West China Second University Hospital Academic / other |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT06182917 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the prognostic significance of minimal residual disease (MRD) detection in patients with ovarian cancer who have low levels of the tumor marker CA125. It aims to assess the risk of recurrence in these patients by utilizing liquid biopsy techniques to detect circulating tumor DNA (ctDNA). The study focuses on patients who have been pathologically confirmed to have ovarian cancer and have a CA125 level of 200 U/ml or less at diagnosis or recurrence. By combining MRD detection with traditional monitoring methods, the study seeks to improve risk assessment for this specific patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-75 with pathologically confirmed ovarian cancer and low CA125 levels.
Not a fit: Patients who are unable to provide sufficient tissue or blood samples for analysis or those with other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management strategies for ovarian cancer patients who are currently underserved by traditional CA125 testing.
How similar studies have performed: While the use of MRD detection in cancer prognosis is an emerging field, this specific approach in CA125 non-sensitive ovarian cancer patients is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-75; * Pathologically confirmed ovarian cancer; * CA125 ≤200U/ml at first diagnosis or recurrence; * Physical condition score PS ≤ 2 points; * Enough tumor samples for WES detection; * Patients and their families can understand and are willing to participate in this study and provide written informed consent. Exclusion Criteria: * Patients unable to provide sufficient tissue / blood samples for research detection; * Pregnant or lactating women; * Other diseases considered by the research doctor to affect the prognosis and survival;
Where this trial is running
Chengdu, Sichuan
- west china second University， SICHUAN University, China — Chengdu, Sichuan, China (Recruiting)
Study contacts
- Principal investigator: Mengpei Zhang — West China Second University Hospital
- Study coordinator: Rutie Yin
- Email: yrtt2013@163.com
- Phone: 028-88570403
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.